Tom Cox is an advisor and consultant to various public companies and private equity firms. Prior to that, Tom was Executive Vice President with MSC Industrial Supply, a NYSE listed global company for 17 years until his retirement in November 2014. In that role his areas of responsibility included Field Sales, Call Centers, Ecommerce, Telesales, National Accounts /Government and he oversaw an organization of approximately 3,000 Associates.
He has extensive experience in sales force effectiveness and acquisitions/integration.
During Tom's tenure, MSC Industrial's sales increased from just over $500 million to close to $3 billion in sales.
OXYS has made considerable progress on a number of initiatives with the military, and the Company anticipates final testing on some initiatives with the military this year. We believe that OXYS could begin showing revenue growth from some of these new products beginning in FY16.
Price target of $1.90. This price target would represent P/S multiples of 10.0x FY15E revenue, 4.0x FY16E revenue, and 2.1x FY17E revenue.
Frisco, Texas, March 31, 2015 – OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), today announced financial and operating results for the fourth quarter and year ended December 31, 2014.
Fiscal Year 2014 Highlights:
• Revenues were $2.4 million, up 35%, led by an 83% increase in revenues in the US
• 10th consecutive quarter of sales growth
• Gross profit was 56% on an adjusted basis
• General & administrative expense was $1.75 million
• Cash was at $647,093
• Capital leases decreased by $309,534
• Long term debt down 42%
• Working capital was a surplus of $418,734
• Current ratio was 1.3
• Total assets increased 7% to $2.5 million
• Net loss per share for the year was $0.10
• Model 615 shipments up 18%; Replacement cartridge shipments up 35%
• Replacement cartridges up to 144% of Model 615 shipped
OxySure to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call at 9:00 am ET on March 31, 2015
FRISCO, TX--(Marketwired - March 25, 2015) - OxySure Systems, Inc. (OTCQB: OXYS) ("OxySure," or the "Company"), the medical device innovator of life-saving easy-to-use emergency oxygen solutions with its "oxygen from powder" technology today announced that it will hold a conference call at 9:00 am ET on Tuesday, March 31, 2015 to discuss its financial results for the three and twelve months ended December 31, 2014.
Mr. Julian Ross, CEO of OxySure, will host the conference call. To join the Audio Conference, please dial the phone number ten minutes prior to the start of the conference call and enter your passcode as follows:
Audience Dial-In: 1 (800) 697-5978 Audience US Toll Free 1 (630) 691-2750 Audience US Toll
Audience Passcode: 6079 959
FRISCO, TX--(Marketwired - March 02, 2015) - OxySure Systems, Inc. (OTCQB: OXYS) ("OxySure," or the "Company"), the medical device innovator of life-saving easy-to-use emergency oxygen solutions with its "oxygen from powder" technology today announced that the Company has been invited to present at the 27th Annual ROTH Conference. Chairman & CEO, Julian T. Ross, and Vice President of Resuscitation Sales, Clark Hood will present a business overview and update on March 11, 2015 at 12:30pm Pacific Time at The Ritz Carlton Hotel Laguna Niguel, located at 1 Ritz Carlton Drive, Dana Point, California. Mr. Ross and Mr. Hood will also be available for one-on-one meetings at the conference on Tuesday March 10 and Wednesday March 11, 2015
FRISCO, TX--(Marketwired - February 18, 2015) - OxySure Systems, Inc. (OXYS) ("OxySure," or the "Company"), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology today announced that the Company has signed a distribution agreement with Stop Heart Attack of Birmingham, Alabama.
It’s an enormous 3D printer which can create an object the size of a phone booth. With a build volume of 1800 x 1000 x 700 mm, the ExOne S-Max printer can, within 24 hours, produce parts of complex shapes and large volumes.
OxySure Systems, Inc. (OTCQB: OXYS) ("OxySure," or the "Company"), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology today announced that the Company has signed a distribution agreement with Chris Gardner and Associates, LLC ("CGA") of Wilton, Connecticut.
CGA is a Veteran owned business that was founded by Chris Gardner, a former EMT and EMS Instructor. CGA is an American Heart Association BLS (Basic Life Support) Instructor and is an Authorized supplier of automated external defibrillators (AEDs) for Cardiac Science, HeartSine, Philips Medical, Physio-Control, and Zoll. Said Clark Hood, VP of Resuscitation Sales for OxySure: "As a former paramedic Chris has a strong background in emergency medical services. We look forward to working with Chris and his team as they target "placement" markets such as school systems, religious organizations, municipalities, corporations, yacht and boat clubs, athletic clubs, sports facilities, and golf clubs."
Nuverra Environmental Solutions (NYSE:NES) was upgraded by equities researchers at Hilliard Lyons from an “underperform” rating to a “neutral” rating in a research report issued on Monday.
"Cardio Partners gives us additional strong in our representation in the Midwest," said Clark Hood, VP of Resuscitation Sales for OxySure. "They bring well over a decade of experience in the placement and management of thousands of AEDs throughout Chicago and across the United States. By adding OxySure to their product portfolio, they now can offer a unique and proprietary resuscitation product to their existing and new customers."
Said Brian Leonard, President and CEO of Cardio Partner Resources: "We are excited about our distribution contract for the OxySure Model 615 portable emergency oxygen device. The Model 615 is FDA approved for OTC (over the counter) use and is a perfect companion product to new and existing AED programs. We can now offer a viable solution to our clients to make the administration of emergency oxygen simple and safe in the work environment."
SeeThruEquity Issues Update Note on OxySure Systems:
"We are maintaining our price target of $2.30 for OxySure. We see the company as a compelling medical device company in the small cap healthcare sector with an innovative medical device with several catalysts ahead. We have modeled strong growth in 2015E; our model calls for the top line to grow from $3.1mn in 2014E, which would represent growth of 72.2% from 2013 levels. Oxysure's management has also reiterated its goal to reach an annual run rate of $10.0mn in 2015E, and we are encouraged by the recent steps taken by the company to achieve this goal. Our target of $2.30 suggests potential upside of 233.3% from the recent price of $0.69 on January 21, 2015."
Meidl is a prolific speaker in the safety industry and a passionate advocate for safety, CPR, emergency preparedness and leadership topics. Meidl has been featured by Oprah, by Matt Lauer and Katie Couric on NBC’s “Today Show,” and various other television shows and magazines. Meidl is passionate about saving lives and paying it forward, and he also supports and has spoken to such groups as the American Heart Association (2014 CPR & First Aid Leadership event), a number of Call 811 and other safety and energy events such as the Western Energy Institute.
“We are excited to welcome Cliff Meidl to our OxySure Team,” said Julian T. Ross, CEO of OxySure. He added, “As an Olympian and CPR recipient, his safety and health mission can continue to resonate with OxySure both in the U.S. and globally.” Meidl shares this excitement. “OxySure has already saved thousands of lives with its innovative portable emergency oxygen system, AEDs and other resuscitation equipment. It is an honor for me to join the OxySure Team moving forward.”
We are revising our estimates and raising the target price from $1.27 to $2.30, which represents 164% upside from the recent price of $0.87 per share.
The agreement appoints HTM Medico as the Company's exclusive distributor in Singapore, and requires an annual minimum purchase commitment of 1,250 units of Model 615, valuing the contract at $1.3 million in the first 5 years.
"Cardiac Life gives us strong representation in the northeast," said Clark Hood, VP of Resuscitation Sales for OxySure. "They bring well over a decade of experience in the placement and management of thousands of AEDs throughout New York and surrounding areas. By adding OxySure to their product portfolio, they now can offer a unique and proprietary resuscitation product to their existing and new customers."
Said Mary Wynne, President of Cardiac Life: "We are excited to add the OxySure Model 615 to our current product offering. We believe emergency oxygen is often overlooked when developing an emergency preparedness program due to the concerns of carrying oxygen tank systems. The Model 615 is FDA approved for OTC (over the counter) use and is a perfect companion product to new and existing AED programs. We can now offer a viable solution to our customers which make the administration of emergency oxygen simple and safe in the workplace. OxySure is a critical component in assuring a successful rescue and we are excited to be able to offer such a life supporting product to our customers."
WEALTHMAKERS, a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report on OxySure Systems (OXYS). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $0.83, the Group Correlation and the projected short squeeze valuation of $4.04 per share.
Said Julian T. Ross, Chairman & CEO of OxySure:
“The Board and I are laser focused on making sure every decision we make delivers the best value for shareholders. By doubling the organic growth plan we get to our previously announced goal of achieving a $10 million revenue run rate in 2015, without, or prior to any external growth options that might be available to us, now or in the immediately foreseeable future. We are and remain committed to our medical device platform strategy, but at each decision point we need to ask ourselves how much dilution we are willing to suffer in return for the additional growth we gain.”
The world’s largest commercial 3D printer has recently produced its first round of prototypes for UK customers.
3Dealise utilised ExOne’s S-Max sand printer, currently the largest and fastest of its kind available on the market, capable of producing prints up to the size of a phone box, to produce the prints that will ship later this month.
This week's show feature interview with Julian Ross, CEO, and Jay Lopez, COO, of OxySure Systems (OXYS), a medical technology company focused on the design, manufacture, and distribution of specialty respiratory and medical solutions.